US Patent 10202454 Anti-PD-L1 monoclonal antibodies and fragments thereof
All edits
Edits on 8 Dec, 2023
Golden AI
Edits made to:
Article (+299 characters)
Article
Patent abstract
The present invention is based, in part, on the discovery of monoclonal antibodies that specifically bind to the cytoplasmic domain of PD-L1 antibodies useful for diagnostic, prognostic, and therapeutic applications, as well as immunoglobulins polypeptides, and nucleic acids thereof.
Edits on 2 Oct, 2023
Golden AI
Edits made to:
Infobox (+2 properties)
Infobox
Patent Inventor Names
Arlene H. Sharpe0
Gordon J. Freeman0
Edits on 27 Sep, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 25 Apr, 2023
Golden AI
Infobox
Patent Citations Received
Edits on 8 Apr, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 26 Sep, 2022
Golden AI
Infobox
Patent Citations Received
Edits on 5 Feb, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent citations received
Edits on 24 Jan, 2022
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 10202454 Anti-PD-L1 monoclonal antibodies and fragments thereof
Infobox
Is a
Patent applicant
Patent jurisdiction
Patent number
10202454
Date of patent
February 12, 2019
Patent application number
15029369
Date Filed
October 24, 2014
Patent primary examiner
Find more entities like US Patent 10202454 Anti-PD-L1 monoclonal antibodies and fragments thereof
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
